Comparison of Ketoralc Tromethamine and Cyclophosphamide Against the Antigenic Peptide of Esr1 (Breast Cancer) using Insilico Techniques
International Journal on Science and Technology · 03.08.2026 · 17 (3)
DOI: 10.71097/ijsat.v17.i3.11461 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal on Science and Technology, online erschienen am 03.08.2026. Verfasst von Anu Augustine und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
To investigate the possible efficacy of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) against the Estrogen Receptor 1 (ESR1) Antigenic peptide (Model Archive (https://modelarchive.org/doi/10.5452/ma-9z6ga) using insilico procedures.
Objectives
The primary goal of our current work is to dock the modelled ESR1 peptide (Breast cancr) with an anti-inflammatory drug. Drug docking studies were performed in order to predict the efficacy of ketoralc tromethamine against ESR1 peptide. Materials and methods: The UniProt database provided the genomic sequence of ESR1-Peptide, which was then docked using the CBDOCK server with ketoralc tromethamine, an anti-inflammatory medication currently in use, and Cyclophosphamide, a control agent. Results and discussion: The current study demonstrates that the reference medication, Cyclophosphamide, and ketoralc tromethamine interact with ESR1-peptide in an efficient manner. The docking score was used to assess the compound's efficacy against the protein that causes breast cancer. Compared to the control medication Cyclophosphamide, ketoralc tromethamine exhibits a higher binding affinity. Therefore, when used in conjunction with novel medications to target the anti-cancer activity protein ESR1 in human breast cancer, ketoralc tromethamine may be considered a viable choice.
Conclusion
This study's conclusion is that anti-cancer medications successfully block ESR1. The results of this study have a substantial influence on the field of current cancer informatics research.
Zitieren
APA
Augustine, A., S, G., & S, S. T. (2026). Comparison of Ketoralc Tromethamine and Cyclophosphamide Against the Antigenic Peptide of Esr1 (Breast Cancer) using Insilico Techniques. International Journal on Science and Technology, 17(3). https://doi.org/10.71097/ijsat.v17.i3.11461
Vancouver
Augustine A, S G, S ST. Comparison of Ketoralc Tromethamine and Cyclophosphamide Against the Antigenic Peptide of Esr1 (Breast Cancer) using Insilico Techniques. International Journal on Science and Technology. 2026;17(3). doi:10.71097/ijsat.v17.i3.11461
BibTeX
@article{Augustine2026,
author = {Augustine, Anu and S, Geethalakshmi and S, Syamkumar T},
title = {Comparison of Ketoralc Tromethamine and Cyclophosphamide Against the Antigenic Peptide of Esr1 (Breast Cancer) using Insilico Techniques},
journal = {International Journal on Science and Technology},
year = {2026},
volume = {17},
number = {3},
doi = {10.71097/ijsat.v17.i3.11461}
}
EUVIMED